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Abstract
Background: While cannabinoid receptor agonists have analgesic activity in inflammatory pain
states they produce a range of side effects. Recently, it has been demonstrated that the arachidonic
acid-amino acid conjugate, N-arachidonyl-glycine (NA-glycine) is effective in acute pain models.
Results: In the present study we examined the effect of NA-glycine in a rat model of inflammatory
pain. Intrathecal administration of NA-glycine (70 – 700 nmol) and the pan-cannabinoid receptor
agonist HU-210 (10 nmol) reduced the mechanical allodynia and thermal hyperalgesia induced by
intraplantar injection of Freund's complete adjuvant (FCA). The actions of HU-210, but not NA-
glycine were reduced by the cannabinoid CB1 receptor antagonist AM251. The cannabinoid CB2
receptor antagonist SR144528 also had no effect on the actions of NA-glycine. In contrast, N-
arachidonyl-GABA (NA-GABA, 700 nmol) and N-arachidonyl-alanine (NA-alanine, 700 nmol) had
no effect on allodynia and hyperalgesia. HU-210, but not NA-glycine produced a reduction in
rotarod latency.
Conclusion:  These findings suggest that NA-glycine may provide a novel non-cannabinoid
receptor mediated approach to alleviate inflammatory pain.
Background
The psychoactive ingredient of Cannabis sativa, ∆9-tetrahy-
drocannabinol (THC), is known to produce its physiolog-
ical actions via an endogenous cannabinoid signalling
system, specifically G-protein coupled cannabinoid CB1
and CB2 receptors [1]. There is now considerable evidence
demonstrating that THC and a number of synthetic can-
nabinoid receptor agonists act via both cannabinoid CB1
and CB2 receptors to reduce the allodynia (pain due to
normally non-noxious stimuli) and hyperalgesia
(increased pain sensitivity to noxious stimuli) associated
with inflammatory pain in animals [2-6]. However, non-
selective cannabinoid agonists produce a spectrum of
motor and psychotropic side effects, which are mediated
by cannabinoid CB1 receptors [7-11].
Cannabinoid receptors are activated by endogenous can-
nabinoids (endocannabinoids), such as arachidonoyl eth-
anolamide (anandamide) and 2-arachidonyl glycerol.
More recently, a number of arachidonyl-amino acid con-
jugates have been identified. One of these, N-arachidonyl
glycine (NA-glycine), is expressed within the central nerv-
ous system, at particularly high levels within the spinal
cord [12,13]. It has been proposed that NA-glycine is
formed via oxidation of anandamide and by conjugation
of glycine with arachidonic acid by arachidonyl-CoA
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[12,13]. NA-glycine differs from the endocannabinoid
anandamide because it displays poor affinity for cannabi-
noid CB1 receptors [14]. Animal studies have shown that
NA-glycine produces analgesia in acute pain models,
reduces the allodynia associated with nerve ligation
induced neuropathic pain and has anti-inflammatory
activity [12,13,15,16]. In the present study we examined
the effects of spinal administration of NA-glycine in an
animal model of inflammatory pain.
Results
Experiments were carried out in animals which had
undergone chronic lumbar intrathecal catheter implanta-
tion. The mechanical paw withdrawal threshold, thermal
paw withdrawal latency and rotarod latency were 14.9 ±
0.1 g, 13.3 ± 1.0 s and 151 ± 18 s prior to, and, 14.9 ± 0.1
g, 13.1 ± 0.7 s and 170 ± 25 s 3 days after intrathecal cath-
eter implantation (n = 18). In one group of animals which
did not receive intraplantar FCA, intrathecal injection of
vehicle produced no significant change in mechanical
paw withdrawal threshold, thermal paw withdrawal
latency, or rotarod latency (P = 0.3 – 0.5 1-way ANOVA, n
= 6).
Effect of NA-glycine on mechanical paw withdrawal 
threshold
We first examined the time course of action of intrathecal
administration of NA-glycine and the pan-cannabinoid
receptor agonist HU-210 on mechanical paw withdrawal
threshold at 24 h after intraplantar injection of FCA. In
these animals, mechanical paw withdrawal threshold var-
ied significantly over time (F7,189 = 65.4, P < 0.0001) and
this differed between treatment groups (F14,189 = 12.0, P <
0.0001). Intraplantar injection of FCA produced a signifi-
cant decrease in mechanical paw withdrawal threshold
(Figure 1A, P < 0.0001). Intrathecal administration of NA-
glycine (700 nmol) produced an increase in mechanical
paw withdrawal threshold which peaked at 1 h and then
declined over the 6 h time course (Figure 1A, n = 8). The
increase in mechanical paw withdrawal threshold was sig-
nificant at 0.5 – 2 h (P = 0.003 – 0.01) and was similar to
the pre-inflammation level at 1 h (P = 0.06). Intrathecal
administration of HU-210 (10 nmol) produced an
increase in mechanical paw withdrawal threshold which
was maintained over the 6 h time course (Figure 1A, n =
6). The increase in mechanical paw withdrawal threshold
was significant at 1 – 6 h (P = 0.007 at 1 h, P < 0.0001 at
2 – 6 h) and was similar to the pre-inflammation level at
1 – 6 h (P = 0.1 at 1 h, P = 1.0 at 2 – 6 h). Intrathecal
administration of vehicle did not produce a significant
change in mechanical paw withdrawal threshold (Figure
1A; P = 1.0, n = 16).
We then assessed the effects of the NA-glycine and HU-
210 on the mean mechanical paw withdrawal threshold,
measured as the AUC. NA-glycine (700 nmol) produced
an increase in the mean mechanical paw withdrawal
threshold in the absence (n = 8) and presence of AM251
(30 nmol, n = 7), or SR144528 (30 nmol, n = 5) which
was significantly greater than that produced by vehicle (n
= 16) (Figure 1B, vehicle versus NA-glycine, P < 0.001;
vehicle versus NA-glycine+AM251, P = 0.007; vehicle ver-
sus NA-glycine+SR144528, P = 0.001). The increase in
mean mechanical paw withdrawal threshold was dose
dependent, with smaller non-significant effects at 70 and
220 nmol doses (Figure 1B, P = 0.9, 0.2, n = 4, 6). HU-210
(10 nmol) produced an increase in the mean mechanical
paw withdrawal threshold in the absence (n = 6), but not
in the presence of AM251 (30 nmol, n = 4), which was sig-
nificantly greater than that produced by vehicle (Figure
1B, vehicle versus HU-210, P < 0.0001; vehicle versus HU-
210+AM251, P = 0.9). When administered alone AM251
(30 nmol, P = 0.9, n = 5) and SR144528 (30 nmol, P = 0.9,
n = 4) had no significant effect on the mean mechanical
paw withdrawal threshold (Figure 1B).
Effect of NA-glycine on thermal paw withdrawal latency
We next examined the time course of action of intrathecal
NA-glycine and HU-210 on thermal paw withdrawal
latency at 24 h after intraplantar injection of FCA. In these
animals, thermal paw withdrawal latency varied signifi-
cantly over time (F7,189 = 59.7, P < 0.0001) and this dif-
fered between treatment groups (F14,189 = 3.2, P = 0.0002).
Intraplantar injection of FCA produced a significant
decrease in thermal paw withdrawal latency (Figure 2A, P
< 0.0001). Intrathecal administration of NA-glycine (700
nmol) produced an increase in thermal paw withdrawal
latency which peaked at 1 h and was maintained over the
6 h time course (Figure 2A, n = 8). The increase in thermal
paw withdrawal latency was significant at 0.5 – 6 h (P =
0.02 – 0.04), but was less than the pre-inflammation level
at all time points (P < 0.01). Intrathecal administration of
HU-210 (10 nmol) produced an increase in thermal paw
withdrawal latency which peaked at 2 – 4 h and was main-
tained over the 6 h time course (Figure 2A, n = 6). The
increase in thermal paw withdrawal latency was signifi-
cant at 0.5 – 6 h (P = 0.03 at 0.5 h, P < 0.001 at 1 – 6 h)
and was similar to the pre-inflammation level at 1 – 4 h
(P = 0.6 – 0.8). Intrathecal administration of vehicle did
not produce a significant change in thermal paw with-
drawal latency (Figure 2A; P = 0.9 – 1.0, n = 16).
NA-glycine (700 nmol) produced an increase in the mean
thermal paw withdrawal latency in the absence (n = 8)
and presence of AM251 (30 nmol, n = 7), or SR144528
(30 nmol, n = 5) which was significantly greater than that
produced by vehicle (n = 16) (Figure 2B, vehicle versus
NA-glycine, P = 0.004; vehicle versus NA-glycine+AM251,
P = 0.009; vehicle versus NA-glycine+SR144528, P =
0.02). The increase in mean thermal paw withdrawalMolecular Pain 2007, 3:24 http://www.molecularpain.com/content/3/1/24
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NA-glycine reduces mechanical allodynia Figure 1
NA-glycine reduces mechanical allodynia. (a) Time plots of the effect of NA-glycine (NAGly,700 nmol, filled circles), HU-
210 (10 nmol, filled squares), or vehicle (open circles) on mechanical paw withdrawal threshold (Mech PWT). Animals received 
an intrathecal injection of NA-glycine, HU-210 or a matched vehicle at time 0 h, 24 h after intraplantar injection of FCA. Data 
is also shown prior to FCA injection (Pre-FCA). (b) Bar charts depicting the effect of intrathecal injection of combinations of 
NA-glycine (NAGly 70 – 700 nmol), HU-210 (10 nmol), AM251 (30 nmol) and vehicle on mean mechanical paw withdrawal 
threshold, measured as the area-under-the-curve (AUC). * denotes P < 0.05, ** P < 0.01 and # P < 0.0001 compared to time 0 
post-FCA in (a) and to vehicle in (b).
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NA-glycine reduces thermal hyperalgesia Figure 2
NA-glycine reduces thermal hyperalgesia. (a) Time plots of the effect of NA-glycine (NAGly,700 nmol, filled circles), 
HU-210 (10 nmol, filled squares), or vehicle (open circles) on thermal paw withdrawal latency (PWL). Animals received an 
intrathecal injection of NA-glycine, HU-210 or a matched vehicle at time 0 h, 24 h after intraplantar injection of FCA. Data is 
also shown prior to FCA injection (Pre-FCA). (b) Bar charts depicting the effect of intrathecal injection of combinations of NA-
glycine (NAGly 70 – 700 nmol), HU-210 (10 nmol), AM251 (30 nmol) and vehicle on mean thermal paw withdrawal latency, 
measured as the area-under-the-curve (AUC). * denotes P < 0.05, ** P < 0.01 and # P < 0.0001 compared to time 0 post-FCA 
in (a) and vehicle in (b).
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latency was dose dependent, with smaller non-significant
effects at 70 and 220 nmol doses (Figure 2B, P = 0.7, 0.2,
n = 4, 6). HU-210 (10 nmol) produced an increase in the
mean thermal paw withdrawal latency in the absence (n =
6), but not in the presence of AM251 (30 nmol, n = 4),
which was significantly greater than that produced by
vehicle (Figure 2B, vehicle versus HU-210, P < 0.0001;
vehicle versus HU-210+AM251, P = 0.5). When adminis-
tered alone AM251 (30 nmol, P = 0.8, n = 5) and
SR144528 (30 nmol, P = 0.9, n = 4) had no significant
effect on the mean thermal paw withdrawal latency (Fig-
ure 2B).
Effect of other arachidonyl-amino acid conjugates
We also examined the effect of two other N-arachidonyl-
amino acid conjugates. NA-GABA (700 nmol, AUC = 7.9
± 2.1 g.h, P = 0.5, n = 7) and NA-alanine (700 nmol, AUC
= 7.2 ± 2.6 g.h, P = 0.6, n = 6) did not produce an increase
in mechanical paw withdrawal threshold significantly
greater than that produced by vehicle (AUC = 0.7 ± 0.7
g.h). Similarly, NA-GABA (700 nmol, AUC = 2.5 ± 3.9 s.h,
P = 0.9, n = 7) and NA-alanine (700 nmol, AUC = 1.6 ±
3.2 s.h, P = 0.9, n = 6) did not produce an increase in ther-
mal paw withdrawal latency which was significantly
greater than that produced by vehicle (AUC = 1.2 ± 1.6
s.h).
Effect of NA-glycine on rotarod latency
We finally examined the time course of action of intrath-
ecal NA-glycine and HU-210 on rotarod latency at 24 h
after intraplantar injection of FCA. In these animals,
rotarod latency varied significantly over time (F5,85 = 3.2,
P = 0.01) and this differed between treatment groups
(F10,85 = 3.1, P = 0.001). Intrathecal administration of NA-
glycine (700 nmol) did not produce a significant change
rotarod latency over the 6 h time course (Figure 3, P = 0.9
– 1.0, n = 5). Intrathecal administration of HU-210 (10
nmol) produced a decrease in rotarod latency which was
significant at 2 – 6 h (Figure 3, P = 0.002 – 0.02, n = 6).
Intrathecal administration of vehicle did not produce a
significant change in rotarod latency over the 6 h time
course (Figure 3; P = 0.8 – 1.0, n = 9).
Discussion
The present study provides the first demonstration that
the arachidonyl-amino acid conjugate NA-glycine reduces
the allodynia and hyperalgesia associated with the FCA-
induced model of inflammation in the rat, although to a
lesser extent than the pan-cannabinoid receptor agonist
HU-210. These observations are consistent with a recent
study in which we demonstrated that spinally delivered
NA-glycine also reduces the allodynia associated with a
nerve-injury induced model of neuropathic pain [16]. In
addition, previous studies have shown that NA-glycine
produces analgesia following systemic administration in
the hot plate test and following intraplantar administra-
tion in the formalin test [12,13]. The effects of NA-glycine
were likely to be mediated by a specific protein because its
actions were dose-dependent and were not reproduced by
the related conjugates, NA-GABA and NA-alanine.
Like cannabinoid CB1 receptors, it has recently been dem-
onstrated that cannabinoid CB2 receptors are expressed in
the central nervous system [17] and may have mediated
some of the effects observed in the present study. It has
previously been demonstrated that systemically delivered
non-selective cannabinoid receptor agonists reduce
inflammatory pain via activation of both CB1 and CB2
receptors [2,4-6,11]. This is consistent with the observa-
tion that like cannabinoid CB1 receptors, CB2 receptors are
expressed within spinal pain pathways and may have cen-
tral analgesic actions, although there appears to some
controversy as to whether this occurs in inflammatory, as
opposed to neuropathic pain models [18-23]. The actions
of intrathecal administration of HU-210 observed in the
present study were likely to have been largely mediated by
cannabinoid CB1 receptors because they were abolished
by the cannabinoid CB1 receptor antagonist AM251. In
contrast, the actions of intrathecal NA-glycine were not
reduced by the cannabinoid CB1 and CB2 receptor antago-
nists, AM251 and SR144528. This is consistent with a
recent study in which we found that AM251 and
SR144528 did not affect the reduction in nerve injury
NA-glycine does not affect motor function Figure 3
NA-glycine does not affect motor function. Time plots 
of the effect of NA-glycine (NAGly,700 nmol, filled circles), 
HU-210 (10 nmol, filled squares), or vehicle (open circles) on 
rotarod latency. Animals received an intrathecal injection of 
NA-glycine, HU-210 or a matched vehicle at time 0 h,24 h 
after intraplantar injection of FCA. Rotarod latency is shown 
as the difference to the latency at the time zero point, with 
negative values indicating a decrease in latency. * denotes P < 
0.05, ** P < 0.01 and # P < 0.0001 compared to time 0.
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induced allodynia produced by intrathecal NA-glycine
[16]. This is also consistent with the moderate affinity of
NA-glycine for the cannabinoid CB1  receptor [14],
although NA-glycine's affinity for cannabinoid CB2 recep-
tor remains to be determined.
NA-glycine may have produced its effects via other endo-
cannabinoid related targets. NA-glycine is a substrate for
the enzyme fatty acid amide hydrolase (FAAH), which is
responsible for anandamide degradation [13,24]. It is
possible that NA-glycine competition with anandamide
for FAAH resulted in increased levels of anandamide,
thereby producing cannabinoid receptor mediated anti-
allodynia. This was unlikely to be responsible the
observed effects because NA-glycine induced anti-allody-
nia was unaffected by cannabinoid receptor antagonists.
The actions of NA-glycine were also unlikely to be due to
activation of the vanilloid receptor TRPV1 because, unlike
the structurally related endocannabinoid anandamide,
NA-glycine does not activate TRPV1 [1,13]. It should also
be noted NA-glycine is also a substrate for cyclooxygenase
2 (COX-2) [25] and a role for COX-2 in the observed
effects cannot be excluded.
While the pharmacology of NA-glycine is still poorly
understood, other targets for NA-glycine are emerging.
NA-glycine is a ligand for the orphan receptor GPR18 [26]
and has complex effects on prostaglandin synthesis [15].
In addition, it has recently been reported that NA-glycine
inhibits the glycine transporter GLYT2, but has little effect
on the glycine and GABA transporters, GLYT1 and GAT1
[27]. It is possible that at least part of the actions of NA-
glycine were mediated by GLYT2 inhibition because
GLYT2 is expressed at high levels within the spinal cord,
and glycine receptor blockade produces allodynia in 'nor-
mal' animals and enhances nociceptive responses in pain
pathways [28-30]. However, NA-alanine and NA-GABA,
which also inhibit GLYT2a [27], had no significant effect
in the present study. Thus, the mechanisms by which NA-
glycine reduces inflammation induced allodynia and
hyperalgesia remain to be determined.
Unlike HU-210, intrathecal NA-glycine had no effect on
motor performance in the rotarod test. This is consistent
with previous observations that intrathecal NA-glycine
does not reduce rotarod performance in animals which
have undergone partial sciatic nerve ligation [16] and that
systemic administration of NA-glycine does not produce
catalepsy in the ring test in normal animals [12]. The triad
of cannabinoid CB1 receptor mediated side effects, includ-
ing depression of spontaneous locomotor activity, cata-
lepsy and hypothermia [e.g. [8]], was not examined in the
present study, however, it has previously been shown that
the rotarod test provides an indicator of cannabinoid CB1
receptor mediated side effects [10]. It should be noted that
NA-glycine may produce motor side effects at higher
doses, but this could not be examined because of solubil-
ity limitations. Equally, lower doses of intrathecal HU-
210 may reduce allodynia without producing motor
effects, as shown previously following systemic adminis-
tration in a neuropathic pain model [9]. In this regard, the
observed effects of NA-glycine were relatively small when
compared to the synthetic cannabinoid HU-210,
although they were of a similar potency and magnitude to
those observed for NA-glycine in other pain models
[13,16]. This relatively low potency may be due to a
number of factors, such as enzymatic degradation which
greatly reduces the effects of the structurally related endo-
cannabinoid anandamide [31].
Conclusion
Overall, the present study has demonstrated that NA-gly-
cine may provide a useful tool for novel pain relieving
strategies. The analgesic actions of NA-glycine may be
complemented by a lack of motor side effects which are
associated with THC and synthetic non-selective cannabi-
noid receptor agonists. Further studies are required to
identify the targets of NA-glycine and more potent and
efficacious ligands for these targets.
Methods
Animals
Male Sprague-Dawley rats, initially weighing between 160
and 200 g, were used for all experiments which were car-
ried out following the guidelines of the NH&MRC 'Aus-
tralian Code of Practice for the Care and Use of Animals
for Scientific Purposes' (7th Edition, 2004) and with the
approval of the Royal North Shore Hospital/University of
Technology Sydney Animal Care and Ethics Committee.
Animals were housed in groups of three, under a 12:12 h
light/dark cycle, with environmental enrichment and free
access to food and water.
The following surgical procedures were carried out under
isoflurane (1 – 3% in O2) anaesthesia. Chronic polyethyl-
ene lumbar intrathecal catheters were inserted between
vertebrae L5–6, advanced 3 cm rostrally and exteriorised
via the occipital region. Intrathecal injections of all agents
were made in gently restrained animals via the exterior-
ised catheter (20 µl of agent, followed by 15 µl flush of
saline to allow for dead-space in the catheter). For the
inflammatory pain model, 0.15 ml of Freund's Complete
Adjuvant (FCA, Sigma, Sydney, Australia) was injected
subcutaneously into the plantar surface of the left hand
paw.
Behavioural measures and protocol
All behavioural testing was carried out in the light cycle.
To assess mechanical allodynia, mechanical paw with-
drawal thresholds were measured with a series of von FreyMolecular Pain 2007, 3:24 http://www.molecularpain.com/content/3/1/24
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hairs (range 0.4 – 15 g). Rats were placed in elevated Per-
spex enclosures (28 cm × 15 cm × 18 cm) with wire mesh
bases and given 15 – 20 min to acclimate to the testing
environment. Each von Frey hair was tested 6 times at ran-
dom locations on the plantar surface of the left hindpaw.
Von Frey hairs were pressed perpendicularly against the
hindpaw and held for approximately 2 s. Testing began
with the 2.0 g von Frey hair. A positive withdrawal
response was noted if the paw was sharply withdrawn, if
any paw licking took place, or if the animal flinched upon
removal of the von Frey filament. If the animal responded
then the next lighter hair was tested. If the animal did not
respond then the next heavier hair was tested. Once there
was a change in response, four more hairs were tested and
the mechanical paw withdrawal threshold was calculated
using the up-down paradigm [32]. If the animals did, or
did not respond to all hairs then the mechanical paw
withdrawal threshold was assigned as 0.2 g, or 15 g,
respectively.
To assess thermal hyperalgesia, thermal paw withdrawal
latency of the left hand paw was measured using a plantar
tester (Ugo Basile, Italy) [33]. Rats were placed in Perspex
enclosures (15 × 15 × 18 cm) and given 10–15 min to
acclimate. Focal infrared heat was applied through the
plastic bottom of the cage to the left hind paw and the
latency for the rat to respond by moving its paw away
from the noxious heat source was recorded. To assess
motor performance, the duration for which the animal
could maintain balance on the rotating drum of a rotarod
device (Ugo Basile, Italy) was measured as the rotarod
latency, with a maximal cut-off time of 300 s.
All animals were allowed to acclimate to their holding
cages for 3 days before any procedures were carried out.
On day 3 animals were tested with all devices, including
multiple training session on the rotarod. On day 4 ani-
mals were implanted with an intrathecal catheter. On days
5 and 6 animals were tested with all devices. On day 6,
catheter placement was confirmed by the occurrence of
bilateral hind limb paralysis following intrathecal injec-
tion of lignocaine hydrochloride (Sigma, Sydney, Aus-
tralia, 2% dissolved in 0.9% saline). Any animals which
did not display rapid, bilateral hind limb paralysis during
the lignocaine test, or displayed abnormal gait following
catheterisation were not used. On day 7, animals received
an intraplantar injection of FCA. On day 8 animals under-
went the experiment. Behavioural testing was carried
twice out over a 60 min period before, then at set time
points over a 6 h period following intrathecal drug injec-
tion. At the end of the experiment animals underwent
another lignocaine test for catheter placement. Each ani-
mal underwent only one experiment.
Drugs
N-[1-oxo-5Z,8Z,11Z,14Z-eicosatetraenyl]-glycine (N-ara-
chidonyl glycine, NA-glycine), 4-[(1-oxo-5Z,8Z,11Z,14Z-
eicosatetraenyl)amino-butanoic acid (N-arachidonyl
GABA, NA-GABA), N-(1-oxo-5Z,8Z,11Z,14Z-eicosatetrae-
nyl)-L-alanine (N-arachidonyl-alanine, NA-alanine) and
1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-
piperidinyl-1H–pyrazole-3-carboxamide (AM251) were
obtained from Cayman Chemicals (Ann Arbor, USA) and
SR144528 was a gift of Sanofi-Synthelabo (Mont Pellier,
France). All drug combinations were made up in a vehicle
solution comprising (V/V%) 6% ethanol and 2% Dime-
thyl sulfoxide in saline on the day of the experiment, and
were injected intrathecally in a total volume of 20 µl, fol-
lowed by a 15 µl flush of 0.9% saline.
Data Analysis
In FCA-treated animals, statistical comparisons of each
behavioural measure over time were made using a two-
way analysis of variance (ANOVA), with time as a within-
subjects factor and drug treatment as a between-subjects
factor. Simple main effects for each behavioural measure
were then tested for individual drug treatment group by
comparing post-inflammation baseline values to post-
intrathecal drug administration values and to pre-inflam-
mation values, using Sidak's adjustment for multiple
comparisons (except rotarod latency which was only com-
pared to post-inflammation baseline values). Mean
changes in allodynia and hyperalgesia produced by drug
injection were calculated as the integral of post-injection
values relative to pre-injection mean baseline (area-
under-the-curve, AUC). Statistical comparisons of each
behavioural AUC measure were made using a one-way
ANOVA. When one-way ANOVAs were significant, post-
hoc comparisons were made using Dunnett's adjustment
for multiple comparisons to the vehicle group. In animals
not treated with FCA statistical comparisons of each
behavioural measure over time were made using a one-
way ANOVA with time as a within-subjects factor. All data
is presented as mean ± S.E.M.
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